Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8648037 | ABBVIE INC | Macrocyclic proline derived HCV serine protease inhibitors |
Jan, 2032
(8 years from now) | |
US8937150 | ABBVIE INC | Anti-viral compounds |
May, 2032
(9 years from now) | |
USRE48923 | ABBVIE INC | Crystal forms |
May, 2035
(12 years from now) | |
US9321807 | ABBVIE INC | Crystal forms |
Jun, 2035
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10028937 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
US10039754 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
US9586978 | ABBVIE INC | Anti-viral compounds |
Nov, 2030
(7 years from now) | |
US10039754
(Pediatric) | ABBVIE INC | Anti-viral compounds |
Dec, 2030
(7 years from now) | |
US10028937
(Pediatric) | ABBVIE INC | Anti-viral compounds |
Dec, 2030
(7 years from now) | |
US9586978
(Pediatric) | ABBVIE INC | Anti-viral compounds |
May, 2031
(8 years from now) | |
US8648037
(Pediatric) | ABBVIE INC | Macrocyclic proline derived HCV serine protease inhibitors |
Jul, 2032
(9 years from now) | |
US8937150
(Pediatric) | ABBVIE INC | Anti-viral compounds |
Nov, 2032
(9 years from now) | |
US10286029 | ABBVIE INC | Method for treating HCV |
Mar, 2034
(11 years from now) | |
US11484534 | ABBVIE INC | Methods for treating HCV |
Mar, 2034
(11 years from now) | |
US10286029
(Pediatric) | ABBVIE INC | Method for treating HCV |
Sep, 2034
(11 years from now) | |
US11484534
(Pediatric) | ABBVIE INC | Methods for treating HCV |
Sep, 2034
(11 years from now) | |
USRE48923
(Pediatric) | ABBVIE INC | Crystal forms |
Nov, 2035
(12 years from now) | |
US9321807
(Pediatric) | ABBVIE INC | Crystal forms |
Dec, 2035
(12 years from now) | |
US11246866 | ABBVIE INC | Solid pharmaceutical compositions for treating HCV |
Jun, 2036
(13 years from now) | |
US11246866
(Pediatric) | ABBVIE INC | Solid pharmaceutical compositions for treating HCV |
Dec, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 3, 2022 |
New Patient Population (NPP) | Apr 30, 2022 |
Orphan Drug Exclusivity (ODE) | Jun 10, 2028 |
New Dosing Schedule (D) | Sep 26, 2022 |
M | Apr 10, 2023 |
Pediatric Exclusivity (PED) | Feb 3, 2023 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
NCE-1 date: February, 2022
Market Authorisation Date: 03 August, 2017
Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7419983 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2024
(1 year, 5 months from now) | |
US7056927 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(1 year, 7 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11459305 | ABBVIE INC | Processes for the preparation of uracil derivatives |
Nov, 2028
(5 years from now) | |
US11045470 | ABBVIE INC | Methods of treating heavy menstrual bleeding |
Mar, 2034
(11 years from now) | |
US10881659 | ABBVIE INC | Methods of treating heavy menstrual bleeding |
Mar, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 23, 2023 |
New Product (NP) | May 29, 2023 |
NCE-1 date: July, 2022
Market Authorisation Date: 29 May, 2020
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7419983 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2024
(1 year, 5 months from now) | |
US7056927 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(1 year, 7 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7176211 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jul, 2024
(1 year, 5 months from now) | |
US11344551 | ABBVIE INC | Methods of treating heavy menstrual bleeding |
Mar, 2034
(11 years from now) | |
US10537572 | ABBVIE INC | Methods of administering elagolix |
Sep, 2036
(13 years from now) | |
US10682351 | ABBVIE INC | Methods of administering elagolix |
Sep, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: July, 2022
Market Authorisation Date: 23 July, 2018
Treatment: Management of moderate to severe pain associated with endometriosis; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women to reduce dysmenorrhea and non-menstrual pelvic pain; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women having dyspareunia associated with endometriosis; Management of moderate to severe pain associated with endometriosis using 150mg elagolix while co-administering rifampin; Management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9499545 | ABBVIE INC | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(8 years from now) | |
US8754096 | ABBVIE INC | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(9 years from now) | |
US9850246 | ABBVIE INC | Process for making CGRP receptor antagonists |
Mar, 2033
(10 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10117836 | ABBVIE INC | Tablet formulation for CGRP active compounds |
Jan, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: Preventive treatment of episodic migraine in adults
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE47221 | ABBVIE INC | Tricyclic compounds |
Dec, 2030
(7 years from now) | |
US8962629 | ABBVIE INC | Tricyclic compounds |
Jan, 2031
(7 years from now) | |
US9951080 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10981923 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US11186584 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10519164 | ABBVIE INC | Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US9963459 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10981924 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10344036 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10550126 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10730883 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US11198697 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10597400 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US11365198 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10202393 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10995095 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US11512092 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Dec 14, 2024 |
New Chemical Entity Exclusivity (NCE) | Aug 16, 2024 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, or when use of those therapies are inadvisable; Treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tnf blockers
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8642538 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(6 years from now) | |
US8420596 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(8 years from now) | |
US8691938 | ABBVIE INC | Anti-viral compounds |
Apr, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 6 months from now) | |
US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 6 months from now) | |
US8268349
(Pediatric) | ABBVIE INC | Solid pharmaceutical dosage form |
Feb, 2025
(2 years from now) | |
US8399015
(Pediatric) | ABBVIE INC | Solid pharmaceutical dosage form |
Feb, 2025
(2 years from now) | |
US9006387 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
US9044480 | ABBVIE INC | Compositions and methods for treating HCV |
Apr, 2031
(8 years from now) | |
US8686026 | ABBVIE INC | Solid compositions |
Jun, 2031
(8 years from now) | |
US8420596
(Pediatric) | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Oct, 2031
(8 years from now) |
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
Market Authorisation Date: 24 July, 2015
Treatment: Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8546399 | ABBVIE INC | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Jun, 2031
(8 years from now) | |
US10730873 | ABBVIE INC | Salts and crystalline forms of an apoptosis-inducing agent |
Nov, 2031
(8 years from now) | |
US8722657 | ABBVIE INC | Salts and crystalline forms of an apoptosis-inducing agent |
Jan, 2032
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9174982 | ABBVIE INC | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
May, 2030
(7 years from now) | |
US11369599 | ABBVIE INC | Melt-extruded solid dispersions containing an apoptosis-inducing agent |
May, 2032
(9 years from now) | |
US10993942 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(10 years from now) | |
US11413282 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(10 years from now) | |
US11110087 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(10 years from now) | |
US9539251 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | May 15, 2026 |
New Indication (I) | May 15, 2022 |
M | Oct 16, 2023 |
Drugs and Companies using VENETOCLAX ingredient
Market Authorisation Date: 11 April, 2016
Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll); Treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnosed acute myeloid leukemia (aml) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy; Treatment of patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up that includes a dose of 50 mg per day for 1 week followed by 100 mg per day for 1 week; Treatment of adults with relapsed, refractory or previously untreated chronic lymphocytic leukemia including a dose ramp-up and in combination with obinutuzumab in multiple 28-day dosing cycles followed by administration in absence of obinutuzumab; Treatment of acute myeloid leukemia (aml) by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine in adults 75 years or older or having certain comorbidities according to a dose ramp-up including a 100 mg per day dose; Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic leukemia (sll) in combination with a ga101 antibody such as obinutuzumab for one or more dosing periods, wherein the cll or sll is a cd20-expressing cancer
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8501238 | ABBVIE INC | Anti-infective agents and uses thereof |
Dec, 2028
(5 years from now) | |
US8188104 | ABBVIE INC | Anti-infective agents and uses thereof |
May, 2029
(6 years from now) | |
US8642538 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(6 years from now) | |
US8420596 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(8 years from now) | |
US8691938 | ABBVIE INC | Anti-viral compounds |
Apr, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 6 months from now) | |
US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 6 months from now) | |
US9139536 | ABBVIE INC | Anti-infective agents and uses thereof |
Nov, 2028
(5 years from now) | |
US9006387 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
US9044480 | ABBVIE INC | Compositions and methods for treating HCV |
Apr, 2031
(8 years from now) | |
US8686026 | ABBVIE INC | Solid compositions |
Jun, 2031
(8 years from now) | |
US8685984 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
US8492386 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
US8466159 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
US8680106 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
US9629841 | ABBVIE INC | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(10 years from now) | |
US10201542 | ABBVIE INC | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(10 years from now) |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.; Use of dasabuvir to inhibit viral replication for the treatment of hcv infection.
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8501238 | ABBVIE INC | Anti-infective agents and uses thereof |
Sep, 2028
(5 years from now) | |
US8188104 | ABBVIE INC | Anti-infective agents and uses thereof |
May, 2029
(6 years from now) | |
US8642538 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(6 years from now) | |
US8420596 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(8 years from now) | |
US8691938 | ABBVIE INC | Anti-viral compounds |
Apr, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 6 months from now) | |
US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 6 months from now) | |
US9139536 | ABBVIE INC | Anti-infective agents and uses thereof |
Nov, 2028
(5 years from now) | |
US9006387 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
US9044480 | ABBVIE INC | Compositions and methods for treating HCV |
Apr, 2031
(8 years from now) | |
US8686026 | ABBVIE INC | Solid compositions |
Jun, 2031
(8 years from now) | |
US10201584 | ABBVIE INC | Compositions and methods for treating HCV |
May, 2032
(9 years from now) | |
US10201541 | ABBVIE INC | Compositions and methods for treating HCV |
May, 2032
(9 years from now) | |
US8492386 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
US8685984 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
US8466159 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
US8680106 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
US10105365 | ABBVIE INC | Solid antiviral dosage forms |
Jan, 2035
(11 years from now) | |
US9333204 | ABBVIE INC | Solid antiviral dosage forms |
Jan, 2035
(11 years from now) | |
US9744170 | ABBVIE INC | Solid antiviral dosage forms |
Jan, 2035
(11 years from now) |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
Market Authorisation Date: 22 July, 2016
Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using dasabuvir/ombitasvir/paritaprevir/ritonavir fixed dose combination; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.; Use of dasabuvir to inhibit viral replication for the treatment of hcv infection.
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10610518 | ABBVIE INC | Presbyopia treatments |
Apr, 2039
(16 years from now) | |
US11285134 | ABBVIE INC | Presbyopia treatments |
Apr, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Oct 28, 2024 |
Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 October, 2021
Treatment: Use of vuity for the treatment of presbyopia in adults
Dosage: SOLUTION;OPHTHALMIC
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic